COVID-19: 'Increased risk' of rare nerve disorder after J&J vaccine

US officials identify 100 preliminary reports of Guillain-Barre Syndrome from 12.5m doses

Last updated:
Vials with a sticker reading, "COVID-19 / Coronavirus vaccine / Injection only" and a medical syringe are seen in front of a displayed Johnson & Johnson logo in this illustration taken October 31, 2020.
Vials with a sticker reading, "COVID-19 / Coronavirus vaccine / Injection only" and a medical syringe are seen in front of a displayed Johnson & Johnson logo in this illustration taken October 31, 2020.
Reuters

Washington: The US Food and Drug Administration on Monday updated its warning labels for the Johnson & Johnson COVID-19 vaccine to include information about an observed “increased risk” of a rare neurological disorder.

Based on analysis of a federal vaccine safety monitoring system, officials have identified 100 preliminary reports of Guillain-Barre Syndrome after approximately 12.5 million doses administered, people familiar with the matter said.

Of these reports, 95 of them were serious and required hospitalization. There was one reported death.

Related Topics:

Get Updates on Topics You Choose

By signing up, you agree to our Privacy Policy and Terms of Use.
Up Next